Bergenin and cetirizine dihydrochloride compound oral administration preparation

Abstract

The invention discloses a compound oral administration preparation containing bergenin\cetirizine dihydrochloride, in particular to a gastric stasis floating type slow-release tablet, which mainly consists of a fast-release coating layer containing the cetirizine dihydrochloride and a slow-release tablet core layer containing the bergenin. The invention further realizes the fast release of the cetirizine dihydrochloride and the gastric stasis and the slow release of the bergenin, and improves the curative effect of the bergenin\cetirizine dihydrochloride compound oral administration preparation. Pharmacodynamic experiments prove that the medicine composition has the obvious effects of relieving the cough, eliminating the phlegm and preventing the asthma, has small side effect, and can be used for treating chronic bronchitis and bronchial asthma.

Description

A kind of petracenin, cetirizine hydrochloride compound oral dosage form technical field The invention belongs to the technical field of medicine, and in particular relates to a compound oral dosage form of petracenin\cetirizine hydrochloride, in particular to a gastric retention floating sustained-release tablet. Background technique Chronic bronchitis and bronchial asthma are clinically common respiratory diseases, and the prevalence rate in my country is as high as 1-4%. Prevalence increases with age, reaching as high as 15 percent or more in people over 50 years of age. The clinical manifestations are long-term repeated cough and expectoration, accompanied by symptoms such as wheezing, shortness of breath, and dyspnea. If it cannot be controlled in time and it is delayed repeatedly, it can deteriorate and develop into chronic obstructive emphysema, cor pulmonale, etc., which will seriously endanger human health and even lead to death. Begenin has a good antitussive ...

AI Technical Summary

Problems solved by technology

Therefore, there are still some unsatisfactory aspects in the curative effect of the existing compound common preparations of petracenin: on the one hand, the shortcoming of low bioavailability of petracenin; on the other hand, chlorpheniramine maleate has both Anticholinergic and strong central nervous system inhibitory effect, easy to cause drowsiness, dizziness, headache and other adverse reactions

Moreover, both medicines have the disadvantage of taking more medicines, which obviously cannot meet the long-term medication requirements of patients with chronic bronchitis and bronchial asthma.

Images